Cellectis Draws €15M EIB Credit Tranche for R&D Funding
Ticker: CLLS · Form: 6-K · Filed: Jan 16, 2024 · CIK: 1627281
Complexity: simple
Sentiment: bullish
Topics: debt-financing, biotechnology, corporate-finance
TL;DR
**Cellectis just secured another €15M from EIB, boosting cash for R&D without shareholder dilution.**
AI Summary
Cellectis S.A., a clinical-stage biotechnology company, announced on January 16, 2024, the drawdown of the second tranche of a €15 million credit facility from the European Investment Bank (EIB). This funding provides Cellectis with additional capital, which is crucial for a biotech company to continue its research and development activities without immediately diluting existing shareholders. For investors, this matters because it indicates the company has secured non-dilutive financing to support its operations and clinical programs.
Why It Matters
This drawdown provides Cellectis with essential non-dilutive funding, allowing them to advance their clinical-stage biotechnology programs without issuing new shares and diluting current shareholders.
Risk Assessment
Risk Level: low — Securing additional funding generally reduces immediate financial risk for a company, especially when it's non-dilutive debt.
Analyst Insight
A smart investor would view this as a positive sign of continued funding for Cellectis's operations, reducing immediate liquidity concerns without shareholder dilution. It suggests the company is executing its financing strategy effectively, which could support its stock price in the short term.
Key Numbers
- €15 million — Second Tranche Drawdown (Represents the additional capital secured by Cellectis from the EIB.)
Key Players & Entities
- Cellectis S.A. (company) — the registrant and borrower
- European Investment Bank (EIB) (company) — the lender providing the credit facility
- André Choulika (person) — Chief Executive Officer of Cellectis S.A.
- €15 million (dollar_amount) — the amount of the second tranche drawn
Forward-Looking Statements
- Cellectis will use the €15 million to fund ongoing research and development for its clinical-stage biotechnology programs. (Cellectis S.A.) — high confidence, target: 2024-12-31
- The company will likely seek further non-dilutive or dilutive financing in the future to sustain its long-term operations, given the capital-intensive nature of biotech. (Cellectis S.A.) — medium confidence, target: 2025-12-31
FAQ
What is the purpose of this 6-K filing by Cellectis S.A.?
The 6-K filing by Cellectis S.A. on January 16, 2024, is to report the drawdown of the second tranche of €15 million under a credit facility agreement with the European Investment Bank (EIB), as detailed in the accompanying Press Release (Exhibit 99.1).
Who signed this 6-K report on behalf of Cellectis S.A.?
The 6-K report was signed by André Choulika, the Chief Executive Officer of Cellectis S.A., on January 16, 2024.
What is the total amount of the credit facility agreement mentioned in the filing?
The filing specifically states the drawdown of the second tranche of €15 million under the credit facility agreement, but it does not specify the total amount of the overall credit facility agreement with the EIB.
How does this funding impact Cellectis's financial strategy?
This funding provides Cellectis with additional capital through a credit facility, which is a form of debt financing. This means the company is securing funds without issuing new shares, thus avoiding dilution for existing shareholders, which is a key benefit for a clinical-stage biotechnology company.
In which registration statements will this 6-K report be incorporated by reference?
This report on Form 6-K, including Exhibit 99.1, shall be deemed incorporated by reference in Cellectis's registration statements on Form F-3 (No. 333-265826) and Form S-8 (Nos. 333-204205, 333-214884, 333-222482, 333-227717, 333-258514, 333-267760 and 333-273777).
Filing Stats: 211 words · 1 min read · ~1 pages · Grade level 9.2 · Accepted 2024-01-16 16:45:04
Filing Documents
- f6k_011624.htm (6-K) — 5KB
- exh_991.htm (EX-99.1) — 7KB
- 0001171843-24-000273.txt ( ) — 13KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Cellectis S.A. (Registrant) Date: January 16, 2024 /s/ Andr Choulika Andr Choulika Chief Executive Officer